Cingulate Inc. Common Stock (CING) Stock Price
CINGStock
$5.33+35.15%52W
Market Cap$77.44M
P/E—
PEG Ratio—
Div yield—
Beta-0.89
CING Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.94%
Price vs S&P 500 (4W)8.71%
VGM Score58.08
CING Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.56 | -$0.45 | +20.12%(+$0.11) | |
| Q1 2026 | -$0.53 | -$0.95 | -80.38%(-$0.42) | |
| Q4 2025 | -$1.55 | -$0.84 | +45.81%(+$0.71) | |
| Q3 2025 | -$0.75 | -$1.35 | -79.52%(-$0.60) | |
| Q2 2025 | -$0.82 | -$1.09 | -32.52%(-$0.27) |
CING Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CINGCingulate Inc. Common Stock | — | — | C | $5.33 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments using its proprietary precision timed-release drug delivery platform. The company focuses on ADHD and anxiety disorders, where less frequent dosing could improve patient outcomes and medication adherence. Cingulate is also evaluating additional therapeutic applications for its platform technology.